

Attached list 16: Effect of sham group in medication studies

| Study              | Disease                  | Parameter                             | Groups             | No  | Before | After | Improve rate |
|--------------------|--------------------------|---------------------------------------|--------------------|-----|--------|-------|--------------|
| Ettlin DA (2006)   | Scaling and root planing | VAS at 120 min                        | Ibuprofen arginine | 32  | 2.6    | 0.2   | 92%          |
|                    |                          |                                       | Sham tablets       | 29  | 4.3    | 1.8   | 58%          |
| Boissel JP (1986)  | Angina                   | Attacks per week decreased at 8 weeks |                    | 27  |        |       | 48%          |
| Grines CL (2002)   | Angina                   | Treadmill exercise time increase      | Gene therapy       | 60  | 9      | 10.7  | 16%          |
|                    |                          |                                       | Sham procedure     | 19  | 9.4    | 10.4  | 10%          |
| PINE MB (1982)     | Angina                   | Epsode of onset per week              | Verapamil          | 18  | 7.4    | 2.44  | 67%          |
|                    |                          |                                       | Sham medicine      | 18  | 7.4    | 4.54  | 39%          |
| Arnold LM (2015)   | Fibromyalgia             | Pain scores                           | Pregabalin         | 181 | 6.7    | 4.84  | 28%          |
|                    |                          |                                       | Placebo            | 177 | 6.7    | 5.45  | 19%          |
| Crofford LJ (2005) | Fibromyalgia             | VAS                                   | Pregabalin         | 128 | 74.8   | 49.49 | 34%          |
|                    |                          |                                       | Placebo            | 129 | 74.8   | 60.63 | 19%          |
| Ohta H (2012)      | Fibromyalgia             | VAS                                   | Pregabalin         | 250 | 6.49   | 5.01  | 23%          |
|                    |                          |                                       | Placebo            | 248 | 6.48   | 5.45  | 16%          |

|                    |                                         |                                     |                                            |     |       |       |     |
|--------------------|-----------------------------------------|-------------------------------------|--------------------------------------------|-----|-------|-------|-----|
| Pirotta S (2015)   | Neuroplasticity                         | knee extension 180 C                | Vitamin D                                  | 13  | 0.75  | 0.88  | 15% |
|                    |                                         |                                     | Placebo                                    | 12  | 0.74  | 0.84  | 12% |
| Dutton SJ (2014)   | Oesophageal cancer                      | Dysphagia                           | Gefitinib                                  | 224 | 20.9  | 1.82  | 91% |
|                    |                                         |                                     | Placebo                                    | 225 | 21.5  | 5     | 77% |
| Reeves KD (2000)   | Knee arthritis                          | Pain with stair use                 | Dextrose Prolotherapy                      | 31  | 5.33  | 3.96  | 26% |
|                    |                                         |                                     | Placebo                                    | 31  | 5.83  | 4.6   | 21% |
| Mameli S (2014)    | Fibromyalgia                            | VASPI: habitual pain                | Oxytocin spray                             | 14  | 67.9  | 62.3  | 8%  |
|                    |                                         |                                     | Placebo                                    | 14  | 66.4  | 51.6  | 22% |
| Pauer L (2011)     | Fibromyalgia                            | Patient Global Impression of Change | Pregabalin                                 | 747 |       |       | 73% |
|                    |                                         |                                     | Placebo                                    |     |       |       | 56% |
| Mease PJ (2008)    | Fibromyalgia                            | Mean pain score                     | Pregabalin                                 | 183 | 7.1   | 5.23  | 26% |
|                    |                                         |                                     | Placebo                                    | 190 | 7.1   | 5.4   | 24% |
| Scadding GK (2014) | Otitis Media with Effusion              | Ear score                           | Fluticasone propionate aqueous nasal spray | 52  | 6.74  | 4.69  | 30% |
|                    |                                         |                                     | Placebo                                    | 48  | 6.83  | 5.48  | 20% |
| Tehranchi A (2014) | Transurethral Resection of the Prostate | Urine frequency                     | Tolterodine                                | 33  | 2.97  | 1.52  | 49% |
|                    |                                         |                                     | Placebo                                    | 31  | 3.26  | 1.97  | 40% |
| Grace D (1999)     | Osteoarthritis of the knee.             | WOMAC                               | Diclofenac                                 | 34  | 46.25 | 33.62 | 27% |
|                    |                                         |                                     | Placebo                                    | 34  | 41.04 | 37.74 | 8%  |

|                   |                             |                       |                                       |     |      |      |     |
|-------------------|-----------------------------|-----------------------|---------------------------------------|-----|------|------|-----|
| Imanaka K (2013)  | Tumor-related pain          | API score             | Hydrocodone                           | 146 | 6.6  | 3.5  | 47% |
|                   |                             |                       | Placebo                               | 147 | 6.6  | 3.8  | 42% |
| Afilalo M (2010)  | Osteoarthritis of the knee  | Pain intensity        | Tapentadol                            | 181 | 7.4  | 4.5  | 39% |
|                   |                             |                       | Oxycodone                             | 118 | 7.3  | 4.7  | 36% |
|                   |                             |                       | Placebo                               | 203 | 7.3  | 5    | 32% |
| Dworkin RH (2009) | Herpes zoster               | Pain in day 1-14 days | CR-oxycodone                          | 21  | 7.6  | 2.5  | 67% |
|                   |                             |                       | gabapentin                            | 24  | 7    | 3.3  | 53% |
|                   |                             |                       | Placebo                               | 27  | 6.7  | 3.7  | 45% |
| Rauck RL (2014 )  | Chronic Low Back Pain       | Pain intensity score  | Hydrocodone Extended-Release Capsules | 151 | 3.1  | 2.62 | 15% |
|                   |                             |                       | Placebo                               | 151 | 3.1  | 2.14 | 31% |
| Rauck RL (2010 )  | Cancer pain                 | Pain intensity score  | Fentanyl buccal soluble film          | 80  | 6.9  | 3.7  | 46% |
|                   |                             |                       | Placebo                               | 71  | 6.9  | 4.6  | 33% |
| Bachert C (2005)  | Respiratory tract infection | Headache              | Aspirin                               | 78  | 6.6  | 3.76 | 43% |
|                   |                             |                       | Acetaminophen                         | 79  | 6.86 | 3.98 | 42% |
|                   |                             |                       | Placebo                               | 78  | 6.12 | 5.78 | 6%  |